FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2001903721> ?p ?o ?g. }

• W2001903721 endingPage "506" @default.
• W2001903721 startingPage "499" @default.
• W2001903721 abstract "In this work, we evaluated combinations of doxorubicin with INNO-206, a (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH) that is currently undergoing two phase II clinical trials, in a primarily chemoresistant tumor indication, i.e. pancreatic cancer. Thus, we compared the antitumor efficacy and tolerability of the following weekly intravenous treatments in the MIA PaCa-2 xenograft model: 3×6 mg doxorubicin (MTD), 3×24 mg/kg DOXO-EMCH (doxorubicin equivalents, MTD), 3×3 mg/kg doxorubicin followed 6h later by 3×12 mg/kg DOXO-EMCH, and 3×12 mg/kg DOXO-EMCH followed 6 h later by 3×3 mg/kg doxorubicin. Whereas therapy with doxorubicin only produced a moderate tumor inhibition, all other therapy arms induced complete and partial remissions up to the end of the experiment on day 43. Although the total amount of doxorubicin equivalents is 72 mg/kg when DOXO-EMCH is administered alone, but only 45 mg/kg doxorubicin equivalents are administered in the combination regimens, the antitumor efficacy in all treated groups was essentially identical, a surprising finding of this study. However, there were significant differences in the tolerability as assessed by the body weight changes: whereas therapy at the MTD of DOXO-EMCH (3×24 mg/kg) produced a body weight loss of -16% including one death, therapy with 3×12 mg/kg DOXO-EMCH followed 6h later by 3×3 mg/kg doxorubicin produced -7% body weight loss, and 3×3 mg/kg doxorubicin followed 6h later by 3×12 mg/kg DOXO-EMCH produced a body weight gain of +2% as a clear indication of minimal systemic toxicity. In addition, cell culture experiments revealed additive to synergistic effects when MIA PaCa-2 cells were exposed to doxorubicin followed 6h later to exposure of the albumin-bound form of DOXO-EMCH spanning a ratio of 1:5 to 5:1 (analyzed for synergistic, additive or antagonistic effects using the software program CalcuSyn(®)). This animal study demonstrates that the time-dependent schedule of an albumin-binding prodrug and a free drug has a critical influence on the overall tolerability. A combination of doxorubicin and DOXO-EMCH is currently being investigated in a phase Ib study." @default.
• W2001903721 created "2016-06-24" @default.
• W2001903721 creator A5004610787 @default.
• W2001903721 creator A5009050214 @default.
• W2001903721 creator A5015081490 @default.
• W2001903721 creator A5039156712 @default.
• W2001903721 creator A5080411036 @default.
• W2001903721 date "2013-01-01" @default.
• W2001903721 modified "2023-09-25" @default.
• W2001903721 title "Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model" @default.
• W2001903721 cites W1506708771 @default.
• W2001903721 cites W1931508686 @default.
• W2001903721 cites W1977887541 @default.
• W2001903721 cites W1978271981 @default.
• W2001903721 cites W1988013867 @default.
• W2001903721 cites W1999401096 @default.
• W2001903721 cites W2012251891 @default.
• W2001903721 cites W2016370062 @default.
• W2001903721 cites W2019786726 @default.
• W2001903721 cites W2025224155 @default.
• W2001903721 cites W2038717222 @default.
• W2001903721 cites W2039108952 @default.
• W2001903721 cites W2050185121 @default.
• W2001903721 cites W2051629559 @default.
• W2001903721 cites W2051747070 @default.
• W2001903721 cites W2061513162 @default.
• W2001903721 cites W2067061342 @default.
• W2001903721 cites W2072264083 @default.
• W2001903721 cites W2077945404 @default.
• W2001903721 cites W2084907141 @default.
• W2001903721 cites W2085121698 @default.
• W2001903721 cites W2101465269 @default.
• W2001903721 cites W2102968118 @default.
• W2001903721 cites W2108473061 @default.
• W2001903721 cites W2128530258 @default.
• W2001903721 cites W2155765426 @default.
• W2001903721 cites W2157590016 @default.
• W2001903721 cites W2163151049 @default.
• W2001903721 cites W4211208840 @default.
• W2001903721 doi "https://doi.org/10.1016/j.ijpharm.2012.11.003" @default.
• W2001903721 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23149257" @default.
• W2001903721 hasPublicationYear "2013" @default.
• W2001903721 type Work @default.
• W2001903721 sameAs 2001903721 @default.
• W2001903721 citedByCount "20" @default.
• W2001903721 countsByYear W20019037212014 @default.
• W2001903721 countsByYear W20019037212015 @default.
• W2001903721 countsByYear W20019037212016 @default.
• W2001903721 countsByYear W20019037212017 @default.
• W2001903721 countsByYear W20019037212018 @default.
• W2001903721 countsByYear W20019037212019 @default.
• W2001903721 countsByYear W20019037212020 @default.
• W2001903721 countsByYear W20019037212021 @default.
• W2001903721 countsByYear W20019037212022 @default.
• W2001903721 crossrefType "journal-article" @default.
• W2001903721 hasAuthorship W2001903721A5004610787 @default.
• W2001903721 hasAuthorship W2001903721A5009050214 @default.
• W2001903721 hasAuthorship W2001903721A5015081490 @default.
• W2001903721 hasAuthorship W2001903721A5039156712 @default.
• W2001903721 hasAuthorship W2001903721A5080411036 @default.
• W2001903721 hasConcept C126322002 @default.
• W2001903721 hasConcept C197934379 @default.
• W2001903721 hasConcept C2776694085 @default.
• W2001903721 hasConcept C2776999253 @default.
• W2001903721 hasConcept C2778375690 @default.
• W2001903721 hasConcept C2781303535 @default.
• W2001903721 hasConcept C71924100 @default.
• W2001903721 hasConcept C98274493 @default.
• W2001903721 hasConceptScore W2001903721C126322002 @default.
• W2001903721 hasConceptScore W2001903721C197934379 @default.
• W2001903721 hasConceptScore W2001903721C2776694085 @default.
• W2001903721 hasConceptScore W2001903721C2776999253 @default.
• W2001903721 hasConceptScore W2001903721C2778375690 @default.
• W2001903721 hasConceptScore W2001903721C2781303535 @default.
• W2001903721 hasConceptScore W2001903721C71924100 @default.
• W2001903721 hasConceptScore W2001903721C98274493 @default.
• W2001903721 hasFunder F4320323556 @default.
• W2001903721 hasIssue "1-2" @default.
• W2001903721 hasLocation W20019037211 @default.
• W2001903721 hasLocation W20019037212 @default.
• W2001903721 hasOpenAccess W2001903721 @default.
• W2001903721 hasPrimaryLocation W20019037211 @default.
• W2001903721 hasRelatedWork W2018180569 @default.
• W2001903721 hasRelatedWork W2051526468 @default.
• W2001903721 hasRelatedWork W2062305226 @default.
• W2001903721 hasRelatedWork W2076364617 @default.
• W2001903721 hasRelatedWork W2118967594 @default.
• W2001903721 hasRelatedWork W2155041167 @default.
• W2001903721 hasRelatedWork W2406715130 @default.
• W2001903721 hasRelatedWork W2433805945 @default.
• W2001903721 hasRelatedWork W3110259941 @default.
• W2001903721 hasRelatedWork W3121007896 @default.
• W2001903721 hasVolume "441" @default.
• W2001903721 isParatext "false" @default.
• W2001903721 isRetracted "false" @default.
• W2001903721 magId "2001903721" @default.
• W2001903721 workType "article" @default.